Subgroups of castration-resistant prostate cancer bone metastases defined through an inverse relationship between androgen receptor activity and immune response. 
1.

Introduction
The growth of normal and malignant prostate tissue is regulated by androgens through activation of the androgen receptor (AR) in both epithelial and stromal cells, and androgen deprivation therapy (ADT) is standard treatment for patients with advanced prostate cancer (PC). However, after an initial period of reduced symptoms and tumor growth, relapse occurs and the PC becomes castration resistant (CRPC). Several mechanisms behind CRPC have been described, including AR amplification, AR mutations, expression of constitutively active AR variants, and intracrine steroid synthesis, as well as AR bypass mechanisms [1] . It has been shown that several new drugs prolong survival and increase quality of life for men with CRPC, including novel AR antagonists, cytostatic drugs, radioisotopes, steroidogenesis inhibitors, immunotherapies, and therapies targeting the tumor microenvironment [2] . Thus, there is a need for biomarkers that can guide CRPC therapy selection. Moreover, the fatal outcome for patients with CRPC highlights the necessity for further therapeutic developments, particularly for patients characterized by low AR activity and for whom no targeting therapy currently exists.
We previously identified heterogeneous gene expression patterns of clinical relevance in metastatic CRPC samples, and found that high levels of the constitutively active AR variant 7 (AR-V7) were associated with particularly poor prognosis [3] . Antonarakis and co-workers showed that detectable levels of AR-V7 in circulating tumors cells are predictive of poor response to AR-targeted therapies [4] . We also found a heterogeneous expression pattern for the steroidogenic enzyme AKR1C3 in clinical samples of CRPC metastases [5] , and the relevance of AKR1C3 as a predictive marker for therapy response to the steroidogenesis inhibitor abiraterone is currently under evaluation.
The aim of this study was to further characterize gene expression in bone metastases from men with CRPC to identify subgroups of relevance for therapy choice.
2.
Patients and methods
Patients
Fresh-frozen bone metastasis samples were obtained from a series of men with PC (n = 65) or other malignancies (n = 14) who underwent surgery for metastatic spinal cord compression at Umeå University
Hospital between 2003 and 2013. The PC patient series has been described before [3, 5, 6] and the clinical characteristics are summarized in Table 1 . Formalin-fixed, paraffin-embedded (FFPE) metastasis samples were available for 41 of the 54 CRPC patients in Table 1 Gleason score (GS) was 7 (n = 10) or 8 (n = 2).
Tissue microarrays (TMAs) were previously constructed from samples taken during transurethral resection of the prostate (TURP) performed between 1975 and 1991 as previously described [7] . Gleason score was reevaluated by one pathologist (L.E.) and TMAs were constructed containing five to eight samples of tumor tissue and four samples of nonmalignant tissue from each patient. For this study, TMAs from 284 patients had tissue available for analysis (Supplementary Table 1 ). The patients had not received cancer therapy before TURP and, according to the therapy traditions in Sweden at that time, the majority (n = 202) were managed via watchful waiting.
The study was approved by the local ethics review board of Umeå University (Dnr 03-185, 2010-240-32, and 02-283).
Tissue preparation
Bone metastasis samples were instantly fresh-frozen in liquid nitrogen or placed in 4% buffered formalin. Fixed samples were decalcified in formic acid before being embedded in paraffin. Fresh radical prostatectomy specimens were received at the pathology department immediately after surgery and cut in 0.5-cm-thick slices before fixation. From these slices, 20 samples were taken using a 0.5-cm skin punch and frozen in liquid nitrogen within 30 min after surgery. The prostate slices were formalin-fixed, embedded in paraffin, cut in 5 mm-thick sections, wholemounted, and stained with hematoxylin-eosin. Tissue sample composition (nonmalignant or malignant) was determined according to location in the whole-mount sections.
RNA extraction
Representative areas of fresh-frozen bone metastasis samples and of malignant and nonmalignant prostate tissue (obtained in pairs from the same patient) were cryosectioned into extraction tubes and RNA was isolated using the Trizol (Invitrogen, Stockholm, Sweden) or AllPrep (Qiagen, Stockholm, Sweden) protocol. The percentage of tumor cells in the samples was determined by examination of parallel sections stained with hematoxylin-eosin, and varied between 50% and 90%. The RNA concentrations were quantified by absorbance measurements using a spectrophotometer (ND-1000; NanoDrop Technologies, Wilmington, DE, USA). The RNA quality was analyzed on a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) and verified to have a RNA integrity number !6.
Whole-genome expression profiling
For each sample, 300 ng of total RNA was amplified using an Illumina 
Real-time RT-PCR
Samples of 200 ng of total RNA were reversed transcribed using a Superscript VILO cDNA synthesis kit (Invitrogen, Stockholm, Sweden) in a total volume of 10 ml. Subsequent qRT-PCR analysis was performed using
TaqMan assays for quantification of HLA-A, TAP1, and PSMB9 mRNA levels (Hs01058806_g1, Hs00388675_m1, and Hs00160610_m1; Life Technologies, Stockholm, Sweden) on an ABI Prism 7900HT sequence detection system according to the manufacturers' protocols. Each sample was run in duplicate and adjusted for the corresponding RPL13A mRNA level (Hs01578912_m1, Life Technologies) using the ddCt method. Statistical differences in mRNA levels between groups were identified using the Kruskal-Wallis test followed by the Mann-Whitney U-test. Paired samples were compared using the Wilcoxon signed-rank test.
Immunohistochemistry
Tissue sections were deparaffinized in xylene and rehydrated in a graded ethanol series. Immunohistochemistry was performed using an Data are presented as median (25th-75th percentile) for continuous variables and as number (precentage) for categorical variables. PSA = prostate-specific antigen. a Castration-resistant patients had disease progression after long-term androgen deprivation therapy including surgical ablation, luteinizing hormone-releasing hormone/GNRH agonist therapy, and therapy with anti-androgens (bicalutamide). b Other malignancies included kidney (n = 3), colorectal (n = 2), lung (n = 1), liver (n = 1), unknown adenocarcinoma (n = 3), myeloma (n = 2), lymphoma (n = 1), and sarcoma (n = 1). c Chemotherapy included taxotere in six cases, estramustine in two cases, and taxotere, carboplatin, and etoposide in one case. d Radiation towards operation site.
ultraView Universal DAB detection kit with the CC1 antigen retrieval HLA class I ABC staining intensity was scored as negative (0), weak (1), moderate (2), or intense (3), and the most common score per sample/ TMA core was recorded. For survival analysis, each patient was represented by the less stained TMA core (median and maximum intensities were evaluated, with similar results; data not shown).
Nuclear AR immunoreactivity in tumor cells was scored according to intensity (0 = negative, 1 = weak, 2 = moderate, 3 = intense staining) and fraction of cells stained (1 = 1-25%, 2 = 26-50%, 3 = 51-75%, 4 = 76-100%). A total score (ranging from 0 to 12) was obtained by multiplying the staining intensity and fraction scores, as previously described [6] . When comparing immunoreactivity between two groups, the MannWhitney U-test and x 2 test were used for continuous and categorical variables, respectively. Survival analysis was performed using the Kaplan-Meier method, with death from PC as events and death from other causes as censored events. Correlations between variables were analyzed using the Spearman rank test.
Results
Whole-genome expression analysis identifies CRPC subgroups according to AR activity
A set of fresh-frozen bone metastases from CRPC patients (n = 40) was characterized and compared to bone metastases from eight untreated PC patients and 12 untreated male patients with other primary malignancies using wholegenome expression profiling and multivariate PCA. The PCA model resulting from analysis of 21 675 gene probe signals included nine significant principal components explaining 45% of the total variation in the expression data. The first component describing the largest variation in the data (R2X=11%, Q2=7%), and thus the most prominent subgroups, was selected for further investigation. It is evident in Figure 1A that the majority of the CRPC bone metastasis samples cluster close to the untreated PC metastases, while some CRPC samples cluster closer to metastases of other malignancies. According to the score values for the first principal component t1 in Figure 1A , the CRPC samples were divided into two groups; samples with positive scores showing high transcript levels of the AR, the AR coregulators FOXA1 and HOXB13, and androgen-regulated genes such as KLK2, KLK3, NKX3.1, STEAP2, and TMPRSS2; and samples with negative scores showing low levels of these gene transcripts (Fig. 1B) . Univariate analysis of differentially expressed genes identified the AR and many AR-regulating and/or AR-regulated gene transcripts among the top genes with positive fold changes in samples with positive compared to negative PCA scores (Supplementary Table 2 ). On the basis of these findings, the 32 CRPC samples with positive PCA scores (80%) were defined as AR-driven and the eight CRPC samples with negative PCA scores (20%) as non-AR-driven. Notably, patients with AR-driven CRPC metastases had higher serum PSA levels than patients with non-AR-driven metastases at the time of metastasis surgery (and borderline higher PSA at diagnosis). No obvious association with previous treatments, presence of soft tissue metastasis, or cancer-specific survival after metastasis surgery[ 4 _ T D $ D I F F ] was found (Supplementary Table 3 ).
Functional differences between AR-driven and non-ARdriven CRPC bone metastases
To examine functional differences between AR-driven and non-AR-driven CRPC samples, the list of differently expressed genes (fold change ! AE 1.5 and p P 0.01, Supplementary Table 2 ) was imported into the Qiagen Ingenuity Pathway Analysis tool for assignment of altered canonical pathways and identification of upstream regulators. According to analysis of 617 upregulated and 906 downregulated gene transcripts, AR-driven CRPC metastases had higher metabolic activity for biosynthesis of cholesterol, pyrimidines, and spermine and degradation of fatty acids and amino acids when compared to non-AR-driven samples (Table 2) . Among the downregulated canonical pathways in ARdriven metastases, the cellular immune response was the most obvious (Table 2 ). Upstream regulators predicted as responsible for the differential expression observed between AR-driven and non-AR-driven CRPC bone metastases are listed in Supplementary Table 4 . AR, SPDEF, and FOXA1 were among the top activated genes that also showed increased mRNA levels in ARdriven metastases, while several immune regulating genes such as TGFB1, INFG, and other cytokines were predicted to be inhibited, and some (CCL5, ETV5, PLAUR, and IFNAR2) also showed reduced mRNA levels (Supplementary Table 4 Fig. 1A-C) . This was accompanied by increased levels of the inhibitory T cell receptors CTLA4 and PDCD1 and lower levels of the proinflammatory Th1 transcription factor TBX21 (Supplementary Fig. 1D-F) , while levels of the stimulatory T-cell receptors ICOS and CD28 and the anti-inflammatory Th2 transcription factor GATA did not differ between non-AR-driven and AR-driven metastases (data not shown). We did not detect mRNA for the regulatory T cell (Treg) transcription factor FOXP3. Non-AR-driven cases had higher levels of CD68, CD163, and S100A9 mRNA ( Supplementary Fig. 1G-I) but not NOS2 mRNA (data not shown), indicating metastasis infiltration of tumor-promoting M2 macrophages and myeloid-derived suppressor cells (MDSCs). The downregulated antigen presentation observed in AR-driven CRPC bone metastases (Table 2 and Supplementary Fig. 2 ) possibly contributed to the low immune-cell infiltration, and this pathway was therefore selected for further examination.
Downregulation of MHC class I expression during PC progression
To verify the PCA findings, we analyzed the expression levels of genes involved in MHC class I antigen processing 
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and presentation (PSMB9, TAP1, and HLA-A) in an extended set of CRPC bone metastasis samples (n = 53), non-treated PC metastases (n = 11), and non-treated metastases from other malignancies (n = 13; Fig. 3 ). Levels in metastases were compared to levels in paired samples of nonmalignant and malignant prostate tissue from radical prostatectomies (n = 12). PSMB9, TAP1, and HLA-A mRNA levels in bone metastases were significantly lower in PC patients than in patients with other malignancies (Fig. 3A-C) . However, and in accordance with the array data, the CRPC bone metastases could be classified into two groups on the basis of their variation in PSMB9, TAP1, and HLA-A mRNA levels (Fig. 3D) , suggesting MHC class I antigen presentation was downregulated in the majority of CRPC bone metastases but preserved in a subgroup of cases. Notably, PSMB9, TAP1, and HLA-A mRNA levels were all significantly lower in malignant compared to nonmalignant prostate tissue and were even lower in bone metastasis tissue (Fig. 3A-C) . Accordingly, immunoreactivity for HLA class I ABC was lower in metastases than in matched primary tumor biopsies obtained at diagnosis (median 37 mo [IQR 16-79 mo] before metastasis surgery; p = 0.037, n = 29; data not shown), indicating a reduction in MHC class I protein expression during PC disease progression.
3.4.
Inverse correlation between MHC class I expression and
nuclear AR immunoreactivity in CRPC metastases
The PCA model indicated downregulated MHC class I antigen presentation in AR-driven CRPC bone metastases compared to preservation of MHC class I antigen presentation in non-AR-driven CRPC bone metastases, so we studied HLA class I ABC immunoreactivity in relation to nuclear AR immunoreactivity (previously measured in those metastases and assumed to reflect AR activity [6] ). HLA class I ABC immunoreactivity in tumor cells was evaluated in metastases for which FFPE tissue was available, and was found to be inversely correlated to the nuclear AR score (Rs = À0.49, p = 0.001, n = 41; Fig. 4 A-D) . Importantly, metastases with moderate to intense HLA class I ABC immunoreactivity showed a significantly higher frequency of CD3 + infiltrating cells than cases with negative to weak immunostaining ( Supplementary Fig. 3 ). Staining heterogeneity was observed for both AR and HLA class I ABC immunoreactivity in many cases, so double staining was performed. Nuclear AR showed a clear inverse staining pattern to HLA class I ABC (Fig. 4E) . FOXA1 staining in consecutive sections indicated reduced but not completely diminished FOXA1 levels in AR-negative/HLA class I ABCpositive tumor cells (Fig. 4F) . staining of tumor cells was associated with higher GS and the presence of metastases at diagnosis (Supplementary Table 1 ). In addition, when patients with metastases (M1) at diagnosis were excluded from the analysis, patients with low (negative to weak) HLA ABC immunoreactivity had shorter cancer-specific survival than patients with moderate to intense immunoreactivity ( Fig. 5B ; p = 0.047, n = 248). In patients managed with watchful waiting (n = 202), a similar but nonsignificant trend was seen ( Fig. 5C ; p = 0.13).
Discussion
We found two subgroups among CRPC bone metastases, defined by high AR activity and low cellular immune responses, or low AR activity and high cellular immune responses. Moreover, CRPC bone metastases with high AR activity seemed to have higher metabolic activities than metastases with low AR activity. To the best of our knowledge, these two CRPC subgroups have not previously been described. Our results confirm previous findings of lower levels of PSMB9, TAP1, and HLA class 1 molecules in PC compared to benign prostate tissue [9] [10] [11] . Importantly, we also present novel data indicating an association between low tumor HLA class I ABC immunoreactivity at diagnosis and poor clinical outcome, as well as markedly lower HLA class I expression in PC bone metastases compared to primary tumors. The subgroups observed had similar expression levels of neuroendocrine and cancer stem-cell markers (Supplementary Table 2 ), and we found no enrichment of tumors negative for MHC class I among docetaxel-treated patients, as previously reported [12] . Not surprisingly, however, AR-V7 mRNA levels were much higher in the ARdriven than in non-AR-driven CRPC metastases, while no differences in AKR1C3 mRNA levels were seen (data not shown and Supplementary Table 2 ). In addition to ARtargeted therapies, we hypothesize that patients with ARdriven CRPC metastases might benefit from therapies targeting cholesterol biosynthesis, b-oxidation, and polyamine synthesis, pathways that were particularly upregulated in this subgroup. This is in line with previous findings by our group of high cholesterol levels and boxidation in CRPC bone metastases [13, 14] . Furthermore, we hypothesize that patients with non-AR-driven CRPC metastases with preserved MHC class I expression will be resistant to all forms of anti-AR therapy, but might instead be susceptible to cancer immunotherapy. Cancer immunotherapy is based on the fact that cancer cells are immunogenic, and the aim of immunotherapy is to strengthen the endogenous antitumor response via immunologic interventions [15] . Tumors develop in an immunesuppressed environment in which cytotoxic CD8 + T cells and NK cells are repressed by inhibitory factors expressed by tumor cells, Tregs, and MDSCs, and in which MDSCs and type M2 macrophages instead promote tumor growth via secretion of factors that stimulate angiogenesis and tumor cell invasion [15, 16] . Most cancer immunotherapies are developed to strengthen cytotoxic T and NK cell activity via tumor vaccination or to inhibit immune checkpoint pathways such as the CTLA-4 or PDCD1/PD-L1 pathways [15] . Very little is known about the immune cell profile in PC [ 1 8 _ T D $ D I F F ] metastases. In primary PC, low tumor infiltration of T cells, B cells, and monocytes has been observed in advanced disease and associated with poor prognosis [17] , although recent studies highlight tumor infiltration of specific lymphocyte/monocyte subtypes, such as FoxP3 + Tregs, CD163 + M2 macrophages, and S100A9-positive inflammatory cells, in lethal PC [18] [19] [20] [21] [22] . High blood fractions of Tregs and MDSC have been related to poor prognosis in patients with CRPC [23] , as have a whole-blood-based mRNA profile mirroring high monocyte/low lymphocyte numbers [24] . Overall, this points to the rationale for using immunotherapy for treatment of PC. Immunotherapies that are being tested in the clinic for treatment of PC include sipuleucel-T (dendritic cell-based vaccine using prostatic acid phosphatase as antigen), Prostvac (viral-based vaccine using PSA as antigen), GVAX (whole-cell-based vaccine), tasquinimod (inhibitor of S100A9 and MDSC), and immune checkpoint inhibitors such as ipilimumab (inhibitor of CTLA-4) and pembrolizumab (inhibitor of PD-1) [25] . Results from the present study highlight heterogeneities among CRPC bone metastases that might be important to consider when choosing immunotherapy for individual PC patients. For instance, the inverse correlation between expression of MHC class I and AR-regulated genes probably diminishes response to antigen-directed vaccines targeting AR-stimulated genes (ACPP and PSA) in the majority of CRPC cases with high AR activity (Supplementary Figure 4) . Instead, the high MHC class I expression, immune cell infiltration, and levels of CTLA4, PDCD1, and S100A9 observed in non-AR-driven metastases suggest testing of immune checkpoint inhibitors and Tasquinimod specifically in this subgroup of patients. However, the current study includes a limited number of clinical CRPC bone metastases, so the subgroup of 20% non-AR-driven cases is particularly small. The results need to be verified in larger cohorts, preferably including patients in trials for evaluation of immune-strengthening therapies. Therapy-predicting markers in addition to low serum PSA levels could be MHC class I expression in tumor cells and the immune cell profile in metastasis tissue and blood. In patients with multimetastatic disease, several metastases should be studied for optimal information. The molecular drivers behind the subgroups of CRPC bone metastases observed are not known and need to be examined further. We observed high levels of the AR co-regulators FOXA1 and HOXB13, which might be responsible for programming the AR cistrome in AR-driven bone metastases [26] , while the function of the prostatederived Ets factor SPDEF in PC is more controversial [27, 28] . The low immune-cell infiltration observed in ARdriven metastases might be explained in part by low levels of LYVE1 (Supplementary Table 4 ) and thus low predicted numbers of lymphatic vessels, recently demonstrated as a critical determinant of the metastatic process in colorectal cancer through reduced immune cytotoxicity [29] . Low levels of the monocyte/lymphocyte chemoattractant CCL5 and predicted low levels of pro-inflammatory cytokines such as IFNG, TNF, CSF2, NFKB, and IL4 could obviously contribute as well. In non-AR-driven metastases, the predicted activity of TGFb1, IL5, and other anti-inflammatory factors might inhibit T-cell activity, possibly via activation of Tregs and MDSC as discussed above (Supplementary Table 4 ). The reduced expression of MHC class I antigen-processing molecules in clinical PC might be caused by structural defects, or possibly by epigenetic, transcriptional, or post-transcriptional regulation [30] . If so, there might be a possibility of restoring MHC class I expression with IFNG or drugs inhibiting methylation or histone deacetylation [11, 31, 32] . The inverse correlation observed between MHC class I expression and AR activity is in line with previous results showing increased lymphocyte density in human prostate after ADT [33, 34] and with the general effects of androgens in suppressing both adaptive and innate immune responses [35] . Taken together, these findings support the rationale for treating PC patients with combinations of ADT and immunotherapy [36] .
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Conclusions
In conclusion, the majority of CRPC bone metastases show high AR activity, high metabolic activity, low MHC class I expression and low numbers of infiltrating immune cells. By contrast, a subgroup of metastases shows low AR and metabolic activity, but high MHC class I expression and immune cell infiltration. Targeted therapies for these two CRPC subgroups should be explored. 
